Trial Profile
Phase 1/2 Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Tanespimycin (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Kosan Biosciences
- 11 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Nov 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 11 Nov 2009 Planned number of patients changed from 50 to 57 as reported by ClinicalTrials.gov.